A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) (NCT06635148)

🧪 Interventions in This Study

• JNJ-81201887 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (104 Sites)

Showing the first 25 of 104 sites.

• Retina Associates Southwest PC — Tucson, Arizona
• Retina Consultants of Orange County — Fullerton, California
• Shiley Eye Institute Jacobs Retina Center — La Jolla, California
• California Retina Consultants — Oxnard, California
• California Eye Medical Specialists — Pasadena, California
• Retina Consultants San Diego — Poway, California
• Bay Area Retina Associates — Walnut Creek, California
• Retina Group of Florida — Fort Lauderdale, Florida
• VitreoRetinal Associates, PA — Gainesville, Florida
• Retina Specialty Institute — Pensacola, Florida
• Retina Vitreous Associates of Florida — St. Petersburg, Florida
• Georgia Retina — Marietta, Georgia
• Marietta Eye Clinic — Marietta, Georgia
• University Retina — Lemont, Illinois
• Midwest Eye Institute — Carmel, Indiana
• Maine Eye Center — Portland, Maine
• Retina Specialists — Baltimore, Maryland
• The Retina Group of Washington — Chevy Chase, Maryland
• Cumberland Valley Retina Consultants — Hagerstown, Maryland
• Ophthalmic Consultants of Boston — Boston, Massachusetts
• Foundation for Vision Research — Grand Rapids, Michigan
• Retina Consultants of Minnesota — Saint Louis Park, Minnesota
• The Retina Institute — St Louis, Missouri
• Sierra Eye Associates — Reno, Nevada
• Retina-Vitreous Surgeons of Central New York — Liverpool, New York

📞 Contact the Study Coordinator

Phone: (844) 434-4210

Email: Participate-In-This-Study1@its.jnj.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Geographic Atrophy

• A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) — Scottsdale, Arizona
• A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration — Bakersfield, California
• Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy — Phoenix, Arizona
• A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy — Gilbert, Arizona
• Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy — Phoenix, Arizona
• A Study in Adults With Geographic Atrophy — Bakersfield, California

Explore by condition: All Geographic Atrophy clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.